1810010M01Rik Inhibitors
Chemical inhibitors of 1810010M01Rik can disrupt its function through various mechanisms by targeting different components of cellular signaling pathways. Wortmannin and LY294002, for example, are potent inhibitors of phosphoinositide 3-kinases (PI3K), which are crucial for the activation of downstream signaling pathways such as Akt. Inhibition by these chemicals would lead to a suppression of any PI3K-dependent activities of 1810010M01Rik. Similarly, if 1810010M01Rik is involved in the MAPK pathway, its function can be inhibited by chemicals like SB203580, which selectively blocks p38 MAP Kinase, or PD98059 and U0126, which inhibit MEK, thereby preventing the activation of ERK. SP600125's ability to inhibit c-Jun N-terminal kinase (JNK) can also interfere with 1810010M01Rik's function if it is associated with JNK signaling.
In cases where 1810010M01Rik's activity is influenced by tyrosine kinases, inhibitors like Dasatinib and Imatinib can be particularly effective. Dasatinib's broad-spectrum inhibition of tyrosine kinases, including Bcr-Abl and Src family kinases, can suppress the protein's function if it is activated by these kinases. Imatinib, by targeting Bcr-Abl, c-Kit, and PDGFR, can also inhibit the function of 1810010M01Rik if it is involved in signaling regulated by these kinases. Rapamycin, which specifically inhibits the mechanistic target of rapamycin (mTOR), would affect 1810010M01Rik's function if it is mTOR-dependent. Additionally, multi-kinase inhibitors like Sorafenib and Sunitinib act on multiple kinases, including Raf, PDGF, and VEGF receptors, which could result in the inhibition of 1810010M01Rik if its function is mediated through these pathways. Lastly, Gefitinib, which inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, can disrupt 1810010M01Rik's activity if it relies on EGFR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of phosphoinositide 3-kinases (PI3K), which can lead to the inhibition of downstream signaling pathways involved in cell survival and proliferation. Since 1810010M01Rik is a protein, if it is associated with PI3K signaling, Wortmannin would inhibit its function via the suppression of this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3Ks, similar to Wortmannin. By inhibiting PI3K, LY294002 can suppress the PI3K/Akt pathway, which may be necessary for the function of various proteins involved in cell survival, growth, and proliferation. Inhibition of this pathway could therefore inhibit the functional activity of 1810010M01Rik if it is involved in PI3K signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP Kinase. If 1810010M01Rik functions downstream of or in conjunction with p38 MAPK signaling, then SB203580 can inhibit the protein's function by blocking this specific kinase's activity, thereby disrupting the signaling cascade that the protein is part of. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK signaling pathway. If 1810010M01Rik is a protein whose activity is dependent on ERK signaling, PD98059 can inhibit its function by preventing the activation of ERK through MEK inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in a signaling pathway that regulates various cellular processes, including cell death and survival. If 1810010M01Rik's function is connected to JNK signaling, inhibition by SP600125 could result in a functional inhibition of the protein. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a potent inhibitor of multiple tyrosine kinases, including Bcr-Abl and Src family kinases. If 1810010M01Rik is activated by or interacts with these kinases, Dasatinib could inhibit the protein's function by blocking the tyrosine kinase activity that is essential for its function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets Bcr-Abl, c-Kit, and PDGFR. If 1810010M01Rik is involved in signaling pathways regulated by these kinases, Imatinib could lead to functional inhibition of the protein by blocking the necessary tyrosine kinase activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. Since ERK is often implicated in cell cycle regulation and survival, if 1810010M01Rik is regulated by this pathway, U0126 can inhibit its function by preventing the activation of ERK. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of the mechanistic target of rapamycin (mTOR), a key kinase in regulating cell growth and metabolism. If the function of 1810010M01Rik is mTOR-dependent, Rapamycin would inhibit its function by directly inhibiting mTOR activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that acts on Raf kinases as well as several receptor tyrosine kinases. If 1810010M01Rik relies on Raf kinase signaling, Sorafenib could inhibit the protein by inhibiting Raf kinase activity. | ||||||